BioXcel Q1 net loss $7.3M; SERENITY At-Home trial fully enrolled, data H2 2025

BioXcel Therapeutics, Inc.

2025-Q1 EPS reported -$1.50 revenue$168,000

Net revenue from IGALMI fell to $168K in Q1 2025 from $582K in Q1 2024.
Net loss of $7.3M improved from $26.8M YoY on lower R&D and SG&A costs.
Cash and equivalents $31M as of March 31, 2025.
SERENITY At-Home pivotal Phase 3 trial fully enrolled; topline data expected H2 2025.
TRANQUILITY In-Care Phase 3 trial for Alzheimer's agitation is advancing toward initiation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.